How does KNRS's PB Ratio compare to its peers?

Insufficient data to calculate KNRS's Price-To-Book Ratio vs. peers for valuation analysis.

How does KNRS's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?

Insufficient data to calculate KNRS's Price-To-Book Ratio vs. industry for valuation analysis.

What is KNRS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate KNRS's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of KNRS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate KNRS's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

KNRS Stock Overview

KNRS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Highly volatile share price over the past 3 months

Does not have a meaningful market cap (CHF4M)

My Notes

Capture your thoughts, links and company narrative

Kinarus Therapeutics Holding AG Competitors

Spexis

SWX:SPEX

CHF 2.0m

Addex Therapeutics

SWX:ADXN

CHF 5.2m

Cosmo Pharmaceuticals

SWX:COPN

CHF 957.9m

OncoZenge

OM:ONCOZ

SEK 46.9m

Price History & Performance

Summary of share price highs, lows and changes for Kinarus Therapeutics Holding
Historical stock prices
Current Share Price	CHF 16.13
52 Week High	CHF 59.14
52 Week Low	CHF 0.90
Beta	0
1 Month Change	-14.29%
3 Month Change	260.00%
1 Year Change	-66.67%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-91.00%

Recent updates

Shareholder Returns

	KNRS	CH Pharmaceuticals	CH Market
7D	5.9%	-1.2%	-2.3%
1Y	-66.7%	2.7%	0.7%

Return vs Industry: KNRS underperformed the Swiss Pharmaceuticals industry which returned -11.4% over the past year.

Return vs Market: KNRS underperformed the Swiss Market which returned -2.5% over the past year.

Price Volatility

Is KNRS's price volatile compared to industry and market?
KNRS volatility
KNRS Average Weekly Movement	83.5%
Pharmaceuticals Industry Average Movement	3.1%
Market Average Movement	3.2%
10% most volatile stocks in CH Market	7.4%
10% least volatile stocks in CH Market	1.6%

Stable Share Price: KNRS's share price has been volatile over the past 3 months.

Volatility Over Time: KNRS's weekly volatility has increased from 64% to 84% over the past year.

About the Company

Founded	Employees	CEO	Website
2017	n/a	Alexander Bausch	www.kinarus.com

Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 mitogen-activated protein kinase inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company was founded in 2017 and is based in Basel, Switzerland.

Kinarus Therapeutics Holding AG Fundamentals Summary

How do Kinarus Therapeutics Holding's earnings and revenue compare to its market cap?
KNRS fundamental statistics
Market cap	CHF 3.85m
Earnings (TTM)	CHF 0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is KNRS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KNRS income statement (TTM)
Revenue	CHF 0
Cost of Revenue	CHF 0
Gross Profit	CHF 0
Other Expenses	CHF 0
Earnings	CHF 0

Last Reported Earnings

n/a

Next Earnings Date

May 24, 2024

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did KNRS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/04/25 06:18
End of Day Share Price	2024/04/25 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kinarus Therapeutics Holding AG is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Andrew Smith	Equity Development Limited